drugset / Trial / NCT04879589
Phase 1 Study of ATRS-2002 in Healthy Male Adults
RandomizedParallel-groupOpen-labelTreatment
Summary
To access the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneously administered ATRA-2002 against commercially available oral formulation of abiraterone acetate in healthy male adults
Timeline
- Start
- 2022-09-01
- Primary completion
- 2023-04-20
- Completion
- 2023-04-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abiraterone acetate | Small molecule | 25 mg | Subcutaneous |
| Subject | Abiraterone acetate | Small molecule | 75 mg | Subcutaneous |
| Subject | Abiraterone acetate | Small molecule | 200 mg | Subcutaneous |
| Subject | Abiraterone acetate | Small molecule | 1000 mg | Subcutaneous |